TINUBU-SQUARE
15.12.2020 15:02:15 CET | Business Wire | Press release
Tinubu® Square Group, the global technology leader in the surety and credit insurance industry, announced today it has acquired the assets of SuretyWave LLC, including its technology and knowledge base, notably the cloud-based surety bond processing system known as SurePath Digital.
The acquisition continues Tinubu Square’s execution of its global strategic vision of building highly complementary and integrated enterprise software solutions and services for credit and surety insurers. This enables clients, brokers, agents, obligees, and carriers to manage their rapidly evolving, high-growth businesses efficiently.
With the acquisition, Tinubu Square’s end-to-end SaaS platform simplifies processing for an entire value chain that has long struggled with disparate, complex surety bond information. Agents, brokers and carrier partners can now efficiently manage their bond requirements, premiums, commission and other calculations.
Tinubu Square is the global leader in designing, producing and servicing the largest providers of financial guarantee products. The Paris-based firm provides technology solutions to 30 of the top 60 credit and surety underwriters in the United States and globally.
Jérôme Pezé, co-founder and CEO, says, “We are now even closer to a global promise of full automation and digitalization of surety and credit insurance products.”
SurePath Digital “is an outstanding insurtech solution because of its proven ability to streamline connections for independent agencies and brokers, which are key business partners to carriers that stand behind bonds,” Pezé adds. “These bond producers add significant value for customers, but desperately need the appropriate technology solution for their business to reduce manual processing, be more efficient for their customers, and grow profitably.”
Earlier this year, Tinubu Square acquired another U.S.-based insurtech, eSURETY®, which provides cloud-based solutions for automated underwriting, account risk analysis, bond lifecycle management and surety analytics at an enterprise level.
“The Tinubu eSURETY solution, its team’s expertise, and its brand recognition brought highly complementary capabilities to our combined existing and future customers,” says Pezé. “What that platform provides for surety carriers, SurePath Digital does for agents and brokers. SurePath significantly reduces the cost of executing and managing surety bonds through automation of administration, processing and reporting functions.
“These capabilities have strengthened our position in the global surety marketplace, providing an end-to-end cloud-based platform,” Pezé adds.
Daniel T. Buckles, deputy CEO and president, surety, of Tinubu Square Americas, notes that the surety bond business “is highly complex but too often still paper-based for multiline agents and brokers and their carrier partners. SurePath Digital is the key to continue to make it less cumbersome so our partners can focus on completing deals. We are building technology bridges in the surety industry where there have been none.”
“We are excited for SurePath Digital to be aligned with an industry leader in Tinubu Square,” says W. Patrick McGinty CPCU, president of SuretyWave. “Existing clients of Tinubu eSURETY and SuretyWave continue to be in safe hands, as the companies concentrate on sustainability and continuity for their software users. Tinubu Square has the same determined focus, innovative technology, and customer-centricity that provide a best-in-class customer experience and product.”
Olivier Placca, Tinubu Square co-founder and group deputy CEO, states, “By investing 20% of revenue in research and development on a yearly basis, Tinubu Square will support further innovation for the benefit of SurePath Digital’s clients. It reinforces our commitment to making this a long-term partnership.”
Placca adds: “Our solution can grow and make an even more significant positive impact in the surety business. Tinubu Square’s enterprise solutions lead the way in supporting an open ecosystem for all players in the surety and credit insurance industry. We are reducing the duplication of tasks, including the many manual tasks still in use. This reduces administrative costs, improves processes and operations, and eases the two-way communication between brokers and agents with underwriters.”
About SuretyWave
In 2017, Steckler Group acquired Insure Vision Technologies (IVT) and renamed the company as SuretyWave. IVT, founded in 1999, was formed to develop a cloud-based surety bond processing system that significantly reduces the cost of executing and managing surety bonds. IVT founders Pam Stocks and Bev Hall helped lead surety industry efforts by being active with ACORD’s standard setting committee for electronic interface between carriers and brokers/agents and with the National Association of Surety Bond Producers (NASBP) Surety Automation Committee and Commercial Surety Committee.
About Tinubu Square
Tinubu® Square is the industry-leading insurtech SaaS (software as a service) platform vendor, enabling credit insurance and surety digital transformation. With 170+ employees globally and 20 years of innovation, Tinubu Square empowers its customers to offer best-in-class client experience; reduce exposure to risk; and lower financial, operational and technology costs. The firm has a footprint with customers in over 20 countries, including 30 of the top 60 worldwide credit and surety underwriters and invests 20% of its annual revenue in research and development. Visit www.tinubu.com/
for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005715/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
